A new assay uses digital loop-mediated isothermal amplification (dLAMP) to perform phenotypic antibacterial susceptibility testing in 30 minutes.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
With growing interest in single-cell sequencing, researchers are looking to increase the throughput while also reducing cost.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
The technology uses DNAzyme-based sensors, fluorescent biomarkers, and a high-throughput particle counter to rapid identify rare targets in complex raw samples.
Researchers from the University of Michigan are beginning to use Drop-Seq to characterize human kidney cells.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
The method simplifies previous techniques, and preliminary testing using a microfluidic device indicates it could ultimately be used in low-resource settings.
The firm discussed its technology, the NIST data, and data from some early customers in a webinar it hosted this week.
Both groups are making their detailed protocols available to researchers online.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.